{
    "clinical_study": {
        "@rank": "82238", 
        "arm_group": [
            {
                "arm_group_label": "Dose extension cohort", 
                "arm_group_type": "Experimental", 
                "description": "Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose.  This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts."
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety of an investigational new drug\n      called PLX3397 when used in combination with Vemurafenib (Zelboraf\u2122)  at different dose\n      levels. Vemurafenib has been approved by the United States Food and Drug Administration\n      (FDA)/European Medicines Agency (EMA) for the treatment of a specific category of\n      unresectable or metastatic melanoma."
        }, 
        "brief_title": "A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma", 
        "condition": [
            "V600-mutated BRAF Unresectable Melanoma", 
            "V600-mutated BRAF Metastatic Melanoma", 
            "Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female \u226518 years old.\n\n          -  Patients with histologically confirmed unresectable Stage III or Stage IV metastatic\n             melanoma who have not been previously treated with a selective BRAF inhibitor.\n\n          -  Presence of a BRAF V600 mutation in the tumor tissue using the cobas BRAF mutation\n             assay or comparable standard of care methodology.\n\n          -  Measurable disease per RECIST v. 1.1 criteria.\n\n          -  ECOG performance status 0 or 1.\n\n        Exclusion Criteria:\n\n          -  Radiation therapy within 14 days of C1D1.\n\n          -  Investigational drug use within 28 days of C1D1.\n\n          -  Patients with active CNS lesions are excluded (i.e., those with radiographically\n             unstable, symptomatic lesions). However, patients treated with stereotactic therapy\n             or surgery are eligible if they remain without evidence of disease progression in the\n             brain for \u22653 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826448", 
            "org_study_id": "PLX108-09"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose extension cohort", 
                    "Cohort 3", 
                    "Cohort 2", 
                    "Cohort 1"
                ], 
                "intervention_name": "PLX3397", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose extension cohort", 
                    "Cohort 3", 
                    "Cohort 2", 
                    "Cohort 1"
                ], 
                "intervention_name": "vemurafenib", 
                "intervention_type": "Drug", 
                "other_name": "Zelboraf"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90024"
                    }, 
                    "name": "UCLA"
                }, 
                "investigator": {
                    "last_name": "Antoni Ribas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80012"
                    }, 
                    "name": "University of Colorado, Denver"
                }, 
                "investigator": {
                    "last_name": "Rene Gonzalez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University"
                }, 
                "investigator": {
                    "last_name": "Jeffrey A Sosman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }, 
                "investigator": {
                    "last_name": "Kim A Margolin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Institute Gustave Roussy"
                }, 
                "investigator": {
                    "last_name": "Caroline Robert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany"
                    }, 
                    "name": "University Hospital Essen"
                }, 
                "investigator": {
                    "last_name": "Dirk Schadendorf, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma", 
        "overall_contact": {
            "email": "hhsu@plexxikon.com", 
            "last_name": "Henry Hsu, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Subjects will take oral doses of PLX3397 and vemurafenib twice a day. Physical examinations, vital signs, 12-lead electrocardiograms (ECG), adverse events, hematology and serum chemistry will be used to assess safety throughout the study. Adverse events will be monitored and reviewed for safety issues/abnormal changes in the above mentioned tests.", 
                "measure": "Safety-Subject incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Patients will have CT scans every 6 weeks for the first 12 weeks and every 9 weeks thereafter. Response to treatment will be evaluated using RECIST 1.1 criteria.", 
                "measure": "Overall response rate - for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "CT scans will be taken every 6 weeks for the first 12 weeks and every 9 weeks thereafter. Response duration is defined as number of days from date of initial response to date of first documented disease progression or death, whichever occurs first.", 
                "measure": "Response Duration - for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "CT scans will be taken every 6 weeks for the first 12 weeks and then every 9 weeks therafter. PFS will be calculated as the number of days from first day of treatment to date of first documented disease progression or date of death, whichever comes first.", 
                "measure": "progression free survival (PFS)-for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Patients will be followed every 3 months for overall survival.", 
                "measure": "overall survival- for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Plexxikon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Plexxikon", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}